Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 1999

View Archived Issues

Amprenavir and other PIs affect fat mass and lipid levels

ViroPharma announces successful VRI program with pleconaril

Tanox tests Hu-901 in peanut allergy

Gabapentin found to reduce symptoms of social anxiety disorder

Interim data released for NeoRx's STR product in multiple myeloma

MPBX's enhancement of doxorubicin activity examined in P388 leukemia

Guerbet discloses new imaging agents

Naturally produced depsipeptides found to possess antibacterial and antiinflammatory activity

Aastrom Biosciences receives SBIR grant for Aastrom Replicell system

Preliminary findings reported for combination HIV vaccine

MTP and/or ApoB secretion inhibitors synthesized at Pfizer

Inhibitors of caspases undergo joint development at Warner-Lambert and BASF

Xanthines acting as inhibitors of PDE4 and/or TNF claimed by Darwin Discovery

Triazine-based inhibitors of angiogenesis designed by Abbott researchers

Ligands for histamine H3 receptors in the pipeline at Sanofi-Synthelabo

Intranasal apomorphine to enter efficacy studies for erectile dysfunction by year end

FDA clears pioglitazone for type II diabetes

Genentech announces R&D highlights from second quarter

PDT with Photofrin cleared in Canada for certain forms of lung cancer

Phytopharm obtains rights to Indian antihepatitis B product

Transplanted human neural stem cells migrate and differentiate

Welsh technology applicable to antiviral drug discovery licensed to Glaxo Wellcome

New cytoprotective compound that acts by inhibiting PARP activity developed at N-Gene

HCV-specific antisense oligonucleotide undergoing advanced preclinical studies at Isis

MGI Pharma to copromote rheumatology product with Pharmacia & Upjohn

Preclinical activity, current status of potent P-glycoprotein inhibitor discussed at congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...